Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report) were down 7.5% on Wednesday . The stock traded as low as $4.64 and last traded at $4.70. Approximately 59,460 shares were traded during mid-day trading, a decline of 94% from the average daily volume of 1,049,645 shares. The stock had previously closed at $5.08.
Virios Therapeutics Stock Down 7.5%
The company has a market cap of $90.51 million, a price-to-earnings ratio of -17.41 and a beta of 1.58. The firm has a 50 day moving average price of $4.99 and a two-hundred day moving average price of $5.53.
Virios Therapeutics Company Profile
(
Get Free Report)
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Virios Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Virios Therapeutics wasn't on the list.
While Virios Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
